Dana Bowers
Assistant Professor, Pharmacotherapy 509-494-7948 Cadwell 104 Yakima


Doctor of Pharmacy, Washington State University
Bachelor of Arts in biology, Central Washington University

Fellowships & Additional Training

Clinical Research Fellowship in infectious diseases, University of Houston College of Pharmacy and Baylor St. Luke’s Medical Center in Houston, Texas

PGY-1 Residency at Providence St. Peter Hospital in Olympia, Wash.


Bowers is currently a clinical assistant professor at the WSU College of Pharmacy and Pharmaceutical Sciences Doctor of Pharmacy program extension located on the PNWU campus in Yakima.


Bowers research interest is in combination therapy for multi-drug resistant Gram-negative bacteria.

Additional Information

Bowers is a member of the Society of Infectious Diseases Pharmacists.

Selected Publications

Bowers DR, Huang V. Emerging Issues and Treatment Strategies in Carbapenem-Resistant Enterobacteriaceae (CRE).Curr Infect Dis Rep. 2016 Dec;18(12):48.

Diep JK, Jacobs DM, Sharma R, Covelli J, Bowers DR, Russo TA, Rao GG. Polymyxin B in Combination with Rifampin and Meropenem against Polymyxin B-Resistant KPC-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2017 Jan 24;61(2).

Bowers DR, Cao H, Zhou J, Ledesma KR, Sun D, Lomovskaya O, Tam VH. Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii. Antimicrob Agents Chemother. 2015 May;59(5):2720-5.

Tam VH, Ledesma KR, Bowers DR, Zhou J, Truong LD. Kidney injury associated with telavancin dosing regimen in an animal model. Antimicrob Agents Chemother. 2015 May;59(5):2930-3.

Bowers DR, Hunter AS, Jacobs DM, Kuper KM, Musick WL, Perez KK, Shah DN, Schilling AN. Significant publications on infectious diseases pharmacotherapy in 2012.Am J Health Syst Pharm. 2013 Nov 1;70(21):1930-40.

Bowers DR, Tam VH. Pseudomonas aeruginosa treatment and transmission reduction. Expert Rev Anti Infect Ther. 2013 Aug;11(8):831-7.

Bowers DR, Liew YX, Lye DC, Kwa AL, Hsu LY, Tam VH. Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. 2013 Mar;57(3):1270-4.

updated 07/26/2017